Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer

Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85  % of all lung cancer cases [1]. Approximately 20–40 % of patients with lung cancer have brain metastases (BMs) at diagnosis or during their disease course [2,3]. The overall survival (OS) of patients with BMs is poor [4]. BMs worsen patients’ quality of life more than other metastases such as bone and liver metastases [5]. The risk of BMs is higher in epidermal growth factor receptor (EGFR)-mutant NSCLC than in EGFR wild-type NSCLC [6].

Source: Lung Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Takehiro Tozuka, Rintaro Noro, Hideaki Mizutani, Futoshi Kurimoto, Taiki Hakozaki, Kakeru Hisakane, Tomoyuki Naito, Satoshi Takahashi, Namiko Taniuchi, Chika Yajima, Yukio Hosomi, Takashi Hirose, Yuji Minegishi, Tetsuya Okano, Koichiro Kamio, Tomoyoshi Ya Source Type: research